{"disease":{"id":"chronic-myelomonocytic-leukemia-cmml","name":"chronic myelomonocytic leukemia cmml"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT07113730","title":"The Kinetics Profiling of Immune Reconstitution and Clinical Outcomes","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":300,"lead_sponsor_name":"Peking University People's Hospital","has_results":false},{"nct_id":"NCT00528983","title":"Safety, Pharmacokinetics, and Pharmacodynamics of Oral Azacitidine in Subjects With Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia and Acute Myelogenous Leukemia","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":133,"lead_sponsor_name":"Celgene","has_results":false},{"nct_id":"NCT06098313","title":"HCT With PTCy in Higher-risk MDS","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":113,"lead_sponsor_name":"Asan Medical Center","has_results":false},{"nct_id":"NCT06950034","title":"A Phase 1 Study of STX-0712 in Patients With Advanced Hematological Malignancies (CMML and AML)","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":105,"lead_sponsor_name":"Solu Therapeutics, Inc","has_results":false},{"nct_id":"NCT03613532","title":"Venetoclax Added to Fludarabine + Busulfan Prior to Transplant and to Maintenance Therapy for AML, MDS, and MDS/MPN","phase":"PHASE1","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":102,"lead_sponsor_name":"Jacqueline Garcia, MD","has_results":false},{"nct_id":"NCT05665530","title":"A Study of PRT2527 as Monotherapy and in Combination With Zanubrutinib or Venetoclax in Participants With R/R Hematologic Malignancies","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":86,"lead_sponsor_name":"Prelude Therapeutics","has_results":false},{"nct_id":"NCT01736683","title":"Study of Sotatercept for the Treatment of Anemia in low-or Intermediate-1 Risk Myelodysplastic Syndromes (MDS) or Non-proliferative Chronic Myelomonocytic Leukemia (CMML)","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":74,"lead_sponsor_name":"Merck Sharp & Dohme LLC","has_results":true},{"nct_id":"NCT04358393","title":"A Study of APG-115 Alone or Combined With Azacitidine in Patients With AML, CMML, or MDS","phase":"PHASE1, PHASE2","overall_status":"UNKNOWN","enrollment_count":69,"lead_sponsor_name":"Ascentage Pharma Group Inc.","has_results":false},{"nct_id":"NCT07128381","title":"Phase I/II Clinical Trial of Axatilimab, a CSF1R Monoclonal Antibody, in Combination With Ruxolitinib as Therapy for Patients With Myelofibrosis (MF) and Chronic Myelomonocytic Leukemia (CMML)","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":66,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":false},{"nct_id":"NCT03922100","title":"Study of NMS-03592088 in Patients With Relapsed or Refractory AML or CMML","phase":"PHASE1, PHASE2","overall_status":"TERMINATED","enrollment_count":63,"lead_sponsor_name":"Nerviano Medical Sciences","has_results":true},{"nct_id":"NCT03526666","title":"Ascorbic Acid Levels in MDS, AML, and CMML Patients","phase":"","overall_status":"COMPLETED","enrollment_count":50,"lead_sponsor_name":"Van Andel Research Institute","has_results":false},{"nct_id":"NCT01842646","title":"Phase II Hedgehog Inhibitor for Myelodysplastic Syndrome (MDS)","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":35,"lead_sponsor_name":"H. Lee Moffitt Cancer Center and Research Institute","has_results":true},{"nct_id":"NCT02749708","title":"Study of IRX5183 in Relapsed and Refractory Acute Myeloid Leukemia and High Risk Myelodysplastic Syndrome","phase":"PHASE1","overall_status":"TERMINATED","enrollment_count":13,"lead_sponsor_name":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","has_results":false},{"nct_id":"NCT06563804","title":"A Study to Evaluate S227928 as a Single Agent and in Combination With Venetoclax in Patients With R/R AML, MDS/AML, or CMML","phase":"PHASE1, PHASE2","overall_status":"TERMINATED","enrollment_count":13,"lead_sponsor_name":"Servier Bio-Innovation LLC","has_results":false},{"nct_id":"NCT05048498","title":"Pharmacokinetics, Tolerability and Safety of NEX-18a","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":2,"lead_sponsor_name":"Nanexa AB","has_results":false},{"nct_id":"NCT04217720","title":"SNS-301 Monotherapy in High Risk MDS and CMML","phase":"PHASE2","overall_status":"WITHDRAWN","enrollment_count":0,"lead_sponsor_name":"Sensei Biotherapeutics, Inc.","has_results":false}],"total":16},"guidelines":[],"source":"Drug Landscape verified database"}